Navigation Links
Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment

BERLIN, May 1, 2007 – Bayer Schering Pharma AG, Germany, announced today new data, which show that immediate initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 percent over three years compared to delayed treatment. These findings from the BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) studies* were presented today at the American Academy of Neurology’s 59th Annual Meeting in Boston, Massachusetts.

“Some patients have already developed significant neurological damage when they first present with signs of MS, which can lead to accumulated disability later in life. The BENEFIT results clearly show that immediate treatment with Betaferon® initiated after the first clinical event can significantly reduce that damage, which could translate into a greater delay in the time it takes for patients to suffer from the debilitating consequences of MS,” said Dr. Mark S. Freedman, Professor of Neurology at the University of Ottawa and investigator of the study. “This is a truly novel finding that has not yet been demonstrated for any other immunomodulatory MS treatment, and underscores the urgent need to treat patients early rather than waiting for further signs of MS to develop. Physicians and patients should consider these unprecedented findings when making treatment decisions.”

“Immediate treatment” refers to treatment initiated after the first clinical event; “delayed treatment” is initiated after the second clinical event or after 2 years, whatever comes first.

“We are delighted that the BENEFIT study continues to deliver ground
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
3. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
4. Point of Care Strep Tests Speed Treatment, Lower Costs
5. Rapid HIV Testing Increases Possibility of Treatment
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Post Your Comments:
(Date:5/5/2015)... BRIDGEWATER, N.J. , May 5, 2015  CorMedix ... developing and commercializing therapeutic products for the treatment of ... 2015 financial results on May 7.  Randy Milby ... investor conference call on Friday, May 8 at 9:00 ... in the conference call, please call 1-877-407-8031 (U.S.), 1-201-689-8031 ...
(Date:5/5/2015)... 5, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... May 11 th before the open, followed by a ... results and business outlook. Participants should call (888) ... (International) and request the InspireMD call. A live webcast of ...
(Date:5/5/2015)... May 5, 2015 GW Pharmaceuticals plc ... a biopharmaceutical company focused on discovering, developing and ... platform, announced today the closing of the previously ... GW of 1,600,000 American Depositary Shares (ADSs) at ... proceeds of approximately $179.2 million (before deducting underwriting ...
Breaking Medicine Technology:CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4
... Oct. 1 VirtualScopics, Inc. (Nasdaq: VSCP ), ... revenues for the third quarter ended September 30, 2010 exceeded ... comparable period in 2009 and a greater than 9% growth ... increased over 30% for the period ended September 30, 2010 ...
... 1 Palatin Technologies, Inc. (NYSE Amex: PTN ... Annual BIO Investor Forum on Wednesday, October 6, 2010 at ... the 9th Annual BIO Investor Forum will take place October ... Carl Spana, Ph.D., President and Chief Executive Officer ...
Cached Medicine Technology:VirtualScopics Revenues Hit Another Quarterly Record 2VirtualScopics Revenues Hit Another Quarterly Record 3
(Date:5/6/2015)... May 06, 2015 More and more people ... created by Brian Flatt, personal trainer and nutritionist. This particular ... 23 pounds in just three weeks or 21 days. , ... been scientifically tested and found to work on all types ... On average, people lose between 12 and 23 pounds using ...
(Date:5/5/2015)... VA (PRWEB) May 06, 2015 Social ... Regulations, Make Social Media Your Most Powerful Marketing Tool ... – Washington, DC, http://www.fdanews.com/SocialMedia , Social media ... dream of social media’s reach. Patients are using it ... their doctors about what they’ve discovered. , But, it ...
(Date:5/5/2015)... 2015 The Journal of ... “ Priority interventions to improve the management of ... research of the ACCORD program ” , As ... actors, including clinicians, patients and family members, managers, ... which included knowledge gap, “work in silos”, lack ...
(Date:5/5/2015)... FL (PRWEB) May 05, 2015 ... company focused on the $1.6 billion peripheral nerve repair ... first quarter ended March 31, 2015 compared to $3.14 ... market’s continued adoption of our proprietary portfolio of nerve ... Connector and AxoGuard® Nerve Protector – and our solid ...
(Date:5/5/2015)... May 05, 2015 The 2015 Crystal Ball, ... to benefit their global research, outreach and patient advocacy programs. ... and awards ceremony that attracted hundreds of supporters. , The ... discovery of the hepatitis B virus (HBV) by Dr. Baruch ... the Nobel Prize in Medicine for his discovery of the ...
Breaking Medicine News(10 mins):Health News:Brian Flatt Announces The 3 Week Diet - A Scientifically Proven Diet Plan 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3
... More than 600 people will gather for the Consortium ... held at the University of Washington in Seattle on ... in global health. The conference is the largest university-based ... all of the major university-based global health programs in ...
... journal Nature , Miguel Godinho Ferreira, Principal Investigator ... lead a team of researchers to shed light on ... of telomeres, the protective tips of chromosomes: while broken ... or cigarette smoke) are quickly joined together, telomeres are ...
... commonly prescribed to treat adolescent acne can increase attention ... fragile X syndrome, the most common inherited cause of ... is the first published on parents, reports of their ... by researchers at the UC Davis MIND Institute, the ...
... By Ellin Holohan HealthDay Reporter , WEDNESDAY, Sept. ... notion that angioplasty, a common procedure to open clogged arteries, ... a new study shows. In fact, the evidence suggests ... heart patients -- people whose condition has not changed recently ...
... fabrics to keep clothing looking fresh and wrinkle-free is unlikely ... article in the current issue of Chemical & Engineering News ... J. Hanson notes that manufacturers have added formaldehyde to fabrics ... care for, particularly to reduce wrinkling in cotton and prevent ...
... team representing the schools of Medicine, Nursing and Social ... clinical pastoral education programs in three Louisville hospitals, has ... Institutes of Health that will fund the development, implementation ... program. Work related to the project will begin immediately. ...
Cached Medicine News:Health News:University, government and philanthropic leaders converge in Seattle to advance global health 2Health News:University, government and philanthropic leaders converge in Seattle to advance global health 3Health News:Why chromosomes never tie their shoelaces 2Health News:Why chromosomes never tie their shoelaces 3Health News:Parents report a widely prescribed antibiotic is effective for fragile X treatment 2Health News:Parents report a widely prescribed antibiotic is effective for fragile X treatment 3Health News:Parents report a widely prescribed antibiotic is effective for fragile X treatment 4Health News:Many Heart Patients Place False Hope in Angioplasty 2Health News:Many Heart Patients Place False Hope in Angioplasty 3Health News:Grant will aid creation of interdisciplinary oncology palliative care education program 2Health News:Grant will aid creation of interdisciplinary oncology palliative care education program 3
Inquire...
Inquire...
... Tura, the new Lulu Guinness Eyewear line ... retro Lulu Guinness herself. This collection brings ... the past with a flair for contemporary ... flair include a sizable collection of prescription ...
... a variety of colors and classic ... styles designed with elegant jewel detail. ... women that are made from the ... in our fine timepieces, Timex branded ...
Medicine Products: